- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Julie Reed: House Hearing Omitted Biosimilar Issues Despite Growing Need for Solutions
The main takeaway from the House Energy and Commerce Committee hearing on HHS's 2023 budget was that biosimilars were not mentioned as much as they should have been, said Julie M. Reed of the Biosimilars Forum.
The main takeaway from the House Energy and Commerce Committee hearing on HHS's 2023 budget was that biosimilars were not mentioned as much as should have been, said Julie M. Reed, the executive director of the Biosimilars Forum.
Transcript
For those who missed it, what were some of the highlights from the House Energy and Commerce Committee hearing regarding the HHS budget for fiscal year 2023?
I think the highlights of that hearing mostly were, from a Biosimilars Forum perspective, it's what we didn't hear. We didn't hear enough about how HHS is going to do more to gain cost savings using biosimilars. How they're going to do more policies that we've been advocating for for years, [addressing] market barriers and improving access to biosimilars.
So, I think that was the most surprising thing for the Biosimilar Forum and our members. We heard a little bit about biosimilars. We've been saying, "Look, there's a solution right here to reduce prescription drug cost overall." It's such a critical, critical year for biosimilars, especially with the 7 biosimilars for Humira [adalimumab] launching next year.
So, we're going to go back and ask HHS to continue to support biosimilars and continue to work with them, especially on those upcoming launches. So, that was our takeaway, and it's now a greater priority for the Forum to get back to HHS.
BioRationality: FDA Clarification Provides New Indications and Process Change for Biosimilars
September 9th 2024Sarfaraz K. Niazi, PhD, explains the FDA's new guidelines on post-approval changes for biosimilars, emphasizing the processes for reporting modifications, comparability assessments, and the potential for biosimilars to introduce new indications or formulation changes, which could significantly impact their market competitiveness and accessibility.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
BioRationality: FDA Opens Up Biosimilar Inquiries on Reddit
August 26th 2024Sarfaraz K. Niazi, PhD, urges stakeholders to engage with the FDA on its Reddit forum—where a representative will answer complex biosimilar questions—encourages clearing misconceptions, and advocates for updates to the Biologics Price Competition and Innovation Act guidelines.
Eye on Pharma: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results
August 21st 2024Celltrion's adalimumab-aaty biosimilar is now accessible for all Costco members, while Amgen sues Samsung Bioepis over the latter’s denosumab biosimilar candidate, and GlycoNex progresses its denosumab biosimilar SPD8 to phase 3 trials.
